Table 3.

Summary of clinical trials of CCBs in AD.

Drug and dose	Study title	Patient population	NCT number	Outcome	Status	Reference
Nitrendipine (10–40 ​mg/day) along with Enalapril maleate (5–20 ​mg/day) and hydrochlorothiazide (12.5–25 ​mg/day)	Double-blind, placebo-controlled Systolic hypotension in Europe (Syst-Eur)	3228	–	The incidence of dementia increased from 32 to 64 cases. As compared to controls, long term therapy of nitrendipine reduced the risk of dementia by 55% from 7.4 to 3.3 cases per 1,000 patient-years (43 versus 21 cases, P ​< ​0.001).	Completed	Forette et al. (2002)
Nilvadipine	European, multicenter, double-blind, placebo-controlled trial in mild to moderate AD	511	NCT02017340	Study results not posted	Phase-3, completed	–